Among HIV-infected persons, 552 had an ADC, 221 had an infection-related NADC, and 388 had an infection-unrelated NADC (Table 2). Thus, counting all ADCs, which have viral etiologies [17,18], and infection-related NADCs, 67% of cancers in HIV-infected persons had a known infectious cause. In contrast, among HIV-uninfected persons, 179 had an ADC, 284 had an infection-related NADC, and 3418 had an infection-unrelated NADC, corresponding to only 12% of cancers with a known infectious cause.
Adjusted rate ratios comparing HIV-infected with HIV-uninfected persons (reference) were 37.7 (P < 0.001) for ADC, 9.2 (P < 0.001) for infection-related NADC, and 1.3 (P < 0.001) for infection-unrelated NADC (Table 2). Rates for most individual infection-related NADCs were significantly elevated in HIV-infected persons, including anal squamous cell (rate ratio = 101.6, P < 0.001), vagina/vulva (rate ratio = 19.5, P < 0.001), Hodgkin's lymphoma (rate ratio = 19.4, P < 0.001), penis (rate ratio = 5.8, P = 0.006), liver (rate ratio = 2.7, P < 0.001), and HPV-related oral squamous cell cancers (rate ratio = 2.0, P = 0.034). Stomach cancer was the only individual infection-related NADC not associated with HIV infection. Infection-unrelated NADCs with increased rates in HIV-infected persons were other anal (rate ratio = 35.3, P < 0.001), nonmelanoma skin (rate ratio = 10.6, P < 0.001), other head and neck (rate ratio = 2.7, P < 0.001), lung (rate ratio = 1.9, P < 0.001), and melanoma (rate ratio = 1.5, P = 0.006); HIV-infected persons also had a lower rate of prostate cancer with a rate ratio of 0.7 (P = 0.002). Other infection-unrelated NADCs were not associated with HIV infection.
As shown in Fig. 2, there was an 8% annual decline (P < 0.001) in infection-related NADCs for HIV-infected persons compared with a 6% annual increase (P = 0.007) for HIV-uninfected persons (P < 0.001 for difference by HIV status). These trends were similar to trends for ADC rates, which declined 12% annually (P < 0.001) for HIV-infected persons and increased 5% annually (P = 0.091) for HIV-uninfected persons (P < 0.001 for difference by HIV status; data not shown). Results for two individual infection-related NADCs, anal squamous cell cancer and Hodgkin's lymphoma, are also shown in Fig. 2. For anal squamous cell cancer, there was a 9% annual decline (P = 0.002) for HIV-infected persons and a 4% annual decline (P = 0.68) for HIV-uninfected persons (P = 0.57 for difference by HIV status). The risk of Hodgkin's lymphoma did not change significantly over time for HIV-infected persons (P = 0.50), but increased by 17% (P = 0.035) among HIV-uninfected persons (P = 0.032 for difference by HIV status). Other infection-related NADCs did not change significantly over time for HIV-infected persons and demonstrated similar trends to HIV-uninfected persons (data not shown). Of note, there were borderline differences comparing annual changes in HIV-infected and HIV-uninfected vagina/vulva cancer rates (−6 vs. 17%; P = 0.087).
The crude rate for infection-unrelated NADCs steeply increased over time for HIV-infected and HIV-uninfected persons (Fig. 2), which was explained by the advancing age of the cohort (Fig. 1). In adjusted models, infection-unrelated NADC rates did not change substantially over time with a 3% annual increase (P = 0.15) for HIV-infected persons and a 1% annual increase (P = 0.066) for HIV-uninfected persons (P = 0.44 for difference by HIV status; Fig. 2). Trends in rates for all individual infection-unrelated NADCs were similar by HIV infection status, and none showed significant changes among HIV-infected persons (data not shown). Of note were borderline differences comparing annual changes in HIV-infected and HIV-uninfected colorectal cancer rates (9 vs. −1%; P = 0.12; data not shown).
We also evaluated whether the association of HIV infection status and cancer risk changed over time (Table 3). The rate ratio (i.e., HIV-infected vs. HIV-uninfected cancer rate) decreased for ADC from 89.9 in 1996–1999 to 22.5 in 2004–2007 (P < 0.001). The rate ratio also decreased for infection-related NADC from 16.9 in 1996–1999 to 6.2 in 2004–2007 (P < 0.001). However, the rate ratio did not change over time for infection-unrelated NADC (P = 0.44). Among individual infection-related NADCs, the rate ratio for anal squamous cell cancer decreased from 159.9 in 1996–1999 to 94.0 in 2004–2007, but differences over time were not statistically significant (P = 0.83). Similarly, the rate ratio for Hodgkin's lymphoma decreased from 43.3 in 1996–1999 to 12.0 in 2004–2007 (P = 0.10). Among infection-unrelated cancers, only lung cancer demonstrated statistically significant differences over time with a rate ratio of 3.9 in 1996–1999 and 2.1 in 2004–2007 (P = 0.010).
We determined that infection-related cancers (ADC and infection-related NADC combined) comprised almost 70% of all cancers in HIV-infected persons enrolled in an integrated healthcare system in California compared with only 12% in HIV-uninfected persons of similar age and sex. HIV-infected persons had a more than nine-fold increased risk of infection-related NADC compared with HIV-uninfected persons, which was largely influenced by differences in the risk of anal squamous cell cancer and Hodgkin's lymphoma. HIV-infected persons also had a 30% increased risk of infection-unrelated NADC compared with HIV-uninfected persons, including a higher risk of other anal, skin, other head and neck, and lung cancers, but lower risk of prostate cancer. Infection-related NADC risk declined over time for HIV-infected persons and increased for HIV-uninfected persons. In contrast, the overall infection-unrelated NADC risk did not change over time for HIV-infected or HIV-uninfected persons.
The substantially greater risk of cancer with a known infectious cause in HIV-infected persons compared with HIV-uninfected persons may be explained by higher virus coinfection rates, as demonstrated by others for human herpesvirus-8, HPV and hepatitis B and C [10–13]. However, general population prevalence for certain viruses, such as Epstein–Barr virus , is very high and cannot account entirely for the large difference observed here for Hodgkin's lymphoma. Alternatively, the greater risk of infection-related cancer observed for HIV-infected persons could be further explained by the fact that the suppressed immune system in HIV-infected persons may reduce the ability to control infections and therefore suppress the oncogenic viral process. This mechanism is supported by a large meta-analysis by Grulich et al.  who compared cancers elevated in persons with HIV infection and organ transplant recipients. These two very different populations have few shared risk factors for cancer except both populations have suppressed immune systems [17,22]. Most of the cancers seen with higher frequency in both populations compared with general population rates had a known infectious cause, including ADC, as well as the same infection-related NADC we report here. Others have demonstrated a higher risk of Hodgkin's lymphoma [2,6,23–26], oral cavity/pharynx [2,23], anal [26,27], liver , and penis  cancers with advanced immunosuppression measured mainly by closer proximity to an AIDS diagnosis [2,23–25] or low CD4+ T-cell counts [4,6,26,27]. One study, however, indicated a nonlinear association of Hodgkin's lymphoma risk and CD4+ T-cell counts .
Further evidence of a strong link between immune function and infection-related cancer risk is provided by our observation that the increased risk of both ADC and infection-related NADC in HIV-infected persons compared with HIV-uninfected persons has narrowed in recent years. This observation is consistent with improvements during the ART era in immune function possibly leading to better control of coinfections [12,15]. In fact, a recent study demonstrated that prolonged ART use predicts hepatitis B virus clearance , although studies of the effect of ART on other viruses were inconclusive, including hepatitis C , anal HPV , cervical HPV , and Epstein–Barr virus . Others have actually demonstrated increases in the incidence of Hodgkin's lymphoma [2,4], anal cancer [4,27,34], and liver  cancer during the ART era, suggesting that these cancers may not be strongly associated with immune reconstitution resulting from ART use. It is not clear why trends are somewhat different in our study, as we observed no changes over time in HIV-infected persons for any cancer in adjusted models, with the exception of declines in anal squamous cell cancer. One possible explanation is that many prior studies compared rates between the pre-ART and ART eras, whereas ours focused only on the ART era. Piketty et al. , for example, in the largest study focusing on anal cancer, found an increasing trend for years 1992–2004, but no change for years 1999–2004. It is also possible that trends may be different for certain subgroups. Our cohort of predominantly HIV-infected white men having sex with men (MSM) had very high anal squamous cell cancer rates early in the ART era. Therefore, it is possible that improvements in immune function may have a bigger impact in our population. Nevertheless, our findings need replication in other settings.
We also report here our finding that the risk of infection-unrelated cancers is only marginally increased in HIV-infected persons compared with HIV-uninfected persons. The meta-analysis by Grulich et al.  demonstrated that other cancers not known to be associated with an infection were also elevated in both immunosuppressed populations, that is, HIV-infected persons and transplant recipients, including lung and kidney cancers, multiple myeloma, and leukemia. Others have linked infection-unrelated cancers and immunosuppression [2,23,24,35,36], most commonly for lung cancer [2,23,35]. However, because the reported increased risk of infection-unrelated cancer is not large, results are more likely to be attributed to unmeasured confounding. Unfortunately, few cohorts have the necessary data for complete adjusted analyses. A recent study of skin cancer suggested that the higher risk of melanoma for HIV-infected persons was more likely due to confounding by sun exposure or perhaps increased medical surveillance than due to immunosuppression . However, there is some indication that the excess risk of lung cancer in HIV-infected persons remains even after accounting for cigarette use [35,38,39]. Thus, a general effect of immune function on some infection-unrelated cancers is possible, but further research is warranted.
The present study had certain limitations. First, we did not account for cancer risk factors such as smoking or alcohol use. However, it is not likely that confounding by these and other factors entirely explained the observed results for cancers with a known infectious cause, given the large effect sizes. Infection-unrelated NADCs, on the other hand, had much smaller effect sizes and may in fact be explained by confounding factors. A related limitation was the ecologic evaluation of changes in cancer risk over time. Although we did adjust for differences in age and sex over time, it is possible that changes in cancer risk factors confounded our results. However, if this were the case, one would expect broader changes in cancer risk, rather than declines only among infection-related cancers. Furthermore, there are no data to suggest that HIV-infected persons have shown dramatic improvements in the prevalence of risk factors, such as smoking, alcohol use, or viral coinfection. Therefore, we believe results are more likely attributable to improvements over time in immune function. Nevertheless, studies incorporating individual-level data are needed to address these questions. Finally, we had limited generalizability to women, the uninsured, and certain racial/ethnic minorities.
The major strength of our study is the selection and follow-up of large, well characterized populations of HIV-infected persons and matched HIV-uninfected persons from the same healthcare system. Study results are likely to be highly generalizable to those with access to healthcare as Kaiser Permanente provides care to approximately 30% of all insured Californians in its most populated areas, and data indicate members are very similar to the local surrounding and statewide population with respect to age, sex, and race/ethnicity, with only slight underrepresentation of those in lower and higher income and education categories . Furthermore, demographics of HIV-infected Kaiser Permanente members are very similar to reported AIDS cases in California . Another strength is the high quality case ascertainment of HIV infection status and cancer diagnoses. Finally, this analysis is unique in that we evaluated differences in the epidemiology of cancers with and without a currently known infectious cause.
In summary, we found that almost 70% of cancers in HIV-infected persons have a currently known infectious cause compared with only 12% in HIV-uninfected persons. These results have implications for prevention of cancers in HIV-infected persons. First, we found little evidence for the need for a different screening approach compared with general guidelines for breast, prostate, or colorectal cancer among HIV-infected persons. However, the higher risk of lung cancer should be evaluated further including the possible association of this cancer with immune function, and the need for greater smoking risk reduction. Prevention efforts in HIV-infected persons, however, should continue to focus on infection-related cancers, including the evaluation of more routine vaccinations for infections such as hepatitis B, and possibly the extension of the recently approved HPV vaccine to adolescent boys. However, the HPV vaccine has not been evaluated in HIV-infected persons, nor has it been evaluated for the prevention of HPV-associated cancers other than cervical cancer. For anal squamous cell cancer, universal screening guidelines for the detection of early lesions may also greatly benefit this population. Finally, our study supports the concept of earlier initiation of ART [41,42], as the burden of infection-related cancers may be reduced further with improved immune function.
The present research was supported in part by grant numbers K01AI071725 and U01-AI069918 from the NIAID, and research grants from KPNC Community Benefit, Garfield Memorial Research Fund and Pfizer Pharmaceuticals. Results were presented in part as an oral presentation (#30) at the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8–11 February 2009, and an oral presentation (#73) at the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies, Bethesda, Maryland, USA, 6–7 October 2008.
M.J.S. was responsible for the overall conception and design of the study, drafting the article, and obtaining funding. C.C. and M.J.S. were responsible for administrative, technical, and logistic support. C.P.Q. provided statistical expertise. W.L., B.T., and L.X. collected and assembled data and performed data analysis. All coauthors were responsible for interpretation of the data, critical revision of the article, and all provided final approval of the article. We also acknowledge Leo Hurley for his critical review of the presented material.
1. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al
. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23:41–50.
2. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al
. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187–194.
3. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al
. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957–1963.
4. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al
. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148:728–736.
5. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007; 19:446–451.
6. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al
. Cancer risk in the Swiss HIV Cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425–432.
7. Hessol NA, Seaberg EC, Preston-Martin S, Massad LS, Sacks HS, Silver S, et al
. Cancer risk among participants in the Women's Interagency HIV study. J Acquir Immune Defic Syndr 2004; 36:978–985.
8. Phelps RM, Smith DK, Heilig CM, Gardner LI, Carpenter CC, Klein RS, et al
. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94:753–757.
9. Murillas J, Del Rio M, Riera M, Vaquer P, Salas A, Leyes M, et al
. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16:113–115.
10. Evans AS, Kaslow RA. Viral infections of humans: epidemiology and control. 4th edition. New York and London: Plenum Medical Book Company; 2006.
11. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948–954.
12. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al
. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226–236.
13. Vallet-Pichard A, Pol S. Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment. J Hepatol 2004; 41:156–166.
14. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13:1–27.
15. Rauch A, Gaudieri S, Evison J, Nolan D, Cavassini M, Weber R, et al
. Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antivir Ther 2008; 13:455–460.
17. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59–67.
18. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030–3044.
19. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26:612–619.
20. Little RJ, Rubin DB. Statistical analysis with missing data. 1st edition. New York, NY: John Wiley and Sons Inc.; 1987.
21. Mueller NE, Birmann B, Parsonnet J, Schiffman M, Stuver S. Infectious agents. Cancer Epidemiology and Prevention.
3rd ed. In: Schottenfeld D, Fraumeni JF, Jr, editors. New York: Oxford University Press; 2006.
22. Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, et al
. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007; 43:2117–2123.
23. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736–1745.
24. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al
. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833–1839.
25. Grulich AE, Wan X, Law MG, Coates M, Kaldor JM. Risk of cancer in people with AIDS. AIDS 1999; 13:839–843.
26. Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep 2008; 5:140–149.
27. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al
. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203–1211.
28. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786–3791.
29. Lee T, Núñez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009; 10:153–159.
30. Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35:873–879.
31. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner H, Jay N, et al
. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001; 28:422–428.
32. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12:1459–1464.
33. Stevens SJ, Blank BS, Smits PH, Meenhorst PL, Middeldorp JM. High Epstein–Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS 2002; 16:993–1001.
34. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143–1153.
35. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207–213.
36. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155–1161.
37. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 2009; 23:385–393.
38. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383–1388.
39. Kirk GD, Merlo C, O' Driscoll P, Mehta SH, Galai N, Vlahov D, et al
. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103–110.
40. California Department of Health Services, Office of AIDS. California AIDS Surveillance Report
, Cumulative Cases as of 31 December 2005.
41. Kitahata M, Gange S, Moore R. Initiating rather than deferring HAART at a CD4 + count >500 cells/mm 3 is associated with improved survival, Paper #71. 16th Conference on Retroviruses and Opportunistic Infections
; 8–11 February 2009; Montreal, Canada.
42. Sterne J. When should HIV-1-infected persons initiate ART? Collaborative analysis of HIV Cohort Studies, Paper #72LB. 16th Conference on Retroviruses and Opportunistic Infections
; 8–11 February 2009; Montreal, Canada.
Keywords:© 2009 Lippincott Williams & Wilkins, Inc.
cancer; cohort; coinfection; HIV; incidence